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Abstract This study examines the association between somatic co-morbidity and both general and disease-specific
health-related quality of life (HRQoL) in patients with asthma and chronic obstructive pulmonary disease (COPD). A
cross-sectional analysiswas done among161COPD patients and 395 asthma patients, aged 40^75 years, recruited from
general practice. In the total study population,47% had no, 32% had one, and 21% had two ormore somatic co-morbid
conditions, withno significantdifferencesbetween asthma andCOPDpatients.Co-morbidityappearedtobe associated
withpoordisease-specific HRQoLin asthma [oddsratio (OR) = 2.08 (1.37^3.18)] andwithpoorgeneral HRQoLin asth-
ma [OR = 2.96 (1.93^4.53)] and COPD [1.81 (0.91^3.60)] patients.Poorest HRQoL was found in patientswithmore than
one co-morbid condition.Cardiacdisease andhypertensionwere associatedwithpoordisease-specific HRQoLin asth-
ma.Of all co-morbid conditions, musculoskeletal disorders were most strongly associated with poor general HRQoL.
Cardiac disease was found to be associated with general and disease-specific HRQoL in asthma but not in COPD. In
studiesonpatientswithasthmaorCOPDaged 40^75 years, co-morbidityshouldbetreatedas adeterminantofHRQoL.
r 2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1463, available online athttp://www.sciencedirect.com
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It is well known that older patients with asthma or
chronic obstructive pulmonary disease (COPD) often
su¡er from other somatic diseases as well. In a study
among asthma and COPD patients 40 years of age and
older, 73% reported one or more other diseases (1). In a
population of oldermale COPDpatients, Ferrer et al. (2)
found that 84% had at least one somatic co-morbid con-
dition. Several studies have examined determinants of
health-related quality of life (HRQoL) in patients with
asthma (3^5) or COPD (6^9). However, not much is
known about the impact of somatic co-morbidity on
HRQoL in COPD patients. This is because in many stu-
dies, patients with signi¢cant co-morbid illness are ex-
cluded (6). The same is true for asthma patients.Recieved 5 February 2002, accepted in revised form19 September 2002
Correspondence should be addressed to:Dr HWijnhoven, EMGO
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1081BTAmsterdam,The Netherlands.Fax: +31-20-4448361Examining the impact of co-morbidity on HRQoL in
asthma or COPD patients is important for several rea-
sons. First of all, the ‘one-disease’ approach often used in
studies on asthma and COPD patients does not re£ect
reality, especially in older patient groups as mentioned
already. Excluding patients with co-morbidity therefore
decreases the external validity of a study. Secondly, it is
important to know whether co-morbidity is a determi-
nant of HRQoL, since if it is, it should be taken into ac-
count as a covariate in clinical trials and descriptive
studies among asthma and COPD patients. Finally, clini-
cians treating asthma and COPD patients should be
aware of the in£uence of co-morbidity on HRQoL, be-
cause itmight change patients’ need for health care.
HRQoL can bemeasured bymeans of disease-speci¢c
or generic questionnaires. Disease-speci¢c question-
naires focus on the in£uence of characteristics of a
particular disease on functioning, while generic ques-
tionnaires focus on the in£uence of general health status
on functioning.Therefore, it is likely that the presence of
CO-MORBIDITYANDQUALITYOFLIFE INASTHMA ANDCOPD 469co-morbidity in patients with asthma or COPD has a
greater impact on general than on disease-speci¢c
HRQoL. In this study, the association between somatic
co-morbidity and both disease-speci¢c and general
HRQoL is examined in asthma and COPD patients aged
40^75 years.
MATERIALSANDMETHODS
Design
The impact of somatic co-morbidity on HRQoL was ex-
aminedin a cross-sectional study, using thebaselinemea-
surement of a longitudinal observational study among
patients with asthma and COPD. An extensive descrip-
tion of the patients andmethods canbe found elsewhere
(10).
Patients
Patients with asthma or COPD were recruited from 25
general practices in three regions of the Netherlands.
The inclusion criteria were: aged16^75 years, capable of
¢lling in a Dutch questionnaire, no speci¢c pulmonary
disease other than asthma or COPD (such as localized
disease of the upper airways, bronchiectasis, and cystic
¢brosis), and absence of any disease in a terminal phase.
Informed consent to participate was obtained. For the
purpose of this study, only patients aged 40^75 years
were included.
The distinctionbetween asthma andCOPDwasmade
by the researcher using pulmonary function measure-
ments, following the1997 revisedguidelines of theDutch
College of General Practitioners for the diagnosis of
asthma and COPD(11). Among the patients selected by
the general practitioner (GP), asthmawas de¢ned as: (1)
a pre (before use of a bronchodilator) FEV1 %pred X
80%; or 2) a combination of a pre-FEV1%predo 80%, a
reversible obstruction (increase in FEV110 min after ad-
ministration of a bronchodilatorX 9% of predicted), and
a post (after use of a bronchodilator) FEV1%predX 80%.
COPD was de¢ned as a pre-FEV1 %pred o 80% com-
bined with an irreversible obstruction (variation in FEV1
before and after bronchodilationo 9% of predicted). Pa-
tients with a mixed disease (10) were excluded.
Measurements
Spirometry
Forced expiratory volume in1s (FEV1) wasmeasured ac-
cording to ATS criteria (12) before (pre-FEV1) and after
(post-FEV1) administration of a bronchodilator (10). FEV1
was expressed as a percentage of the predicted FEV1
(FEV1 %pred) using the adult predicted normals of the
European Community for Coal and Steel (13).Quality of life
HRQoLwasmeasuredby a disease-speci¢c and a generic
(general) questionnaire.The disease-speci¢c instrument
usedwas the Quality Of Life in Respiratory Illness Question-
naire (QoL-RIQ) of MailleŁ and Kaptein (14). This written
questionnaire was especially developed and validated
for patients with asthma and COPD treated primarily in
general practice, who generally have mildly to moder-
ately severe disease. It contains 55 items divided into se-
ven subscales: (1) breathing problems; (2) physical
problems; (3) emotions; (4) situations triggering or en-
hancing breathing problems; (5) general activities; (6)
daily and domestic activities; and (7) social activities, re-
lationships and sexuality. For every item, patients were
asked to answer, on a seven-point Likert-type scale, to
whatdegree they were troubleddue to pulmonary com-
plaints.The response categories of all items ranged from
1 (not troubled at all) to 7 (verymuch troubled). Cronba-
ch’s a’s varied from 0.68 to 0.92 for the domain subscales,
and was 0.92 for the overall score (14). In case of missing
data, o 50% missing items were allowed per subscale
and were substituted, and one missing subscale was al-
lowed for the calculation of the overall score (15).
The generic instrumentusedwas theDutchversion of
the Nottingham Health Pro¢le (NHP) (16). The NHP is a
self-administered two-part questionnaire designed to
measure the respondent’s subjective perception of his
or her health status (17). In this study, only part one of
the questionnaire was used which contains 38 state-
ments relating to six dimensions: (1) physical mobility;
(2) pain; (3) sleep; (4) energy; (5) social isolation; and (6)
emotional reactions. Patients were asked whether or
not the item applied to them. Positive answers were
given the appropriate weight, according to their relative
severity (18). Each dimension score ranges from 0
(= optimal) to 100. No missing data were allowed for
calculation of a dimension score. An overall score was
calculated by adding all dimension scores divided by six.
Although the use of an overall score for the NHP is not
widely accepted (19), it was considered appropriate for
the purpose of this study (2).
Co-morbidity
Patients were questioned about co-morbidity by trained
interviewers administering a questionnaire during a
face-to-face interview.The questionnaire included ques-
tions on the presence or absence of speci¢c chronic dis-
eases (yes/no): (1) diabetesmellitus; (2) hypertension; (3)
cardiac disease (including cardiac arrhythmia, previous
myocardial infarction, angina pectoris, and congestive
heart failure); (4) cerebrovascular disease [stroke or
transient ischemic attack (TIA)]; (5) musculoskeletal dis-
orders [including arthritis (osteoarthritis or rheumatoid
arthritis) and chronic back pain]; and (6) malignancies. In
470 RESPIRATORYMEDICINEaddition, patients were asked whether they had any
other chronic disease. Compared to information ob-
tained from GP’s, self-reports of chronic diseases were
found to be su⁄ciently accurate (20).Co-morbidity was
de¢ned as: (1) presence of co-morbidity (yes/no); (2)
number of co-morbid conditions (0/1/Z2); (3) presence
of speci¢c co-morbidity.
Statistical analyses
Analyses were performed using the statistical package
SPSS.9.0.Patientswithmissing values on pulmonary func-
tion, co-morbidity or HRQoL were excluded from the
analyses. All analyses were performed separately for
asthma and COPD patients.
Since scores onboth general (NHP) anddisease-speci-
¢c HRQoL (QoL-RIQ) were not normally distributed,
they were dichotomized at themedianvalue of the total
studypopulation.HRQoLwas coded as 0when the score
was lower than or equal to the median value (good
HRQoL) and1when the scorewas higher than themed-
ian value (poor HRQoL).The samewas done for all sub-
scale scores.The association between co-morbidity and
HRQoL was examined using logistic regression analyses
with HRQoL (the dichotomized total scores and sub-
scale scores of both the QoL-RIQ and the NHP) as the
dependent variable and co-morbidity as the independent
variable. The association between HRQoL and speci¢c
chronic diseases was studied multivariately only when
the prevalence of the speci¢c chronic disease was 10%
or higher.For speci¢c chronic diseases with a prevalence
lower than 10% a variable ‘remaining chronic diseases’
was computed (yes or no). All regression models were
adjusted for age and gender, since these variables are
likely to be associatedwithbothHRQoL and co-morbid-
ity. Interaction was tested between disease group (asth-
ma or COPD) and co-morbidity in order to examine
whether or not the impact of co-morbidity di¡ered be-
tween the asthma and COPD groups.
RESULTS
A total of1254 patients with asthma or COPD, aged 40^
75 [mean age¼ 57711 (SD); 47% male], was selected by
the GP to be included in the study.Of those, 505 refused
to participate, leaving 749 patients [mean age ¼ 57711
(SD); 45% male; 65.2% asthma, 27.4% COPD, and 7.5%
mixed disease]. After excluding patients with missing
data on co-morbidity or HRQoL, 603 patients [mean
age ¼ 56 7 11 (SD); 46% male; 65.5% asthma, 26.7%
COPD, and 7.8% mixed disease] were left.Only patients
with asthma (n = 395) orCOPD (n = 161)were included in
this study.
Table1presents the characteristics of the study popu-
lation separately for asthma and COPD patients.COPDpatients were generally older than asthma patients and
reportedpoorerHRQoL. Inboth the asthma and COPD
group approximately 55% of the patients reported at
least one somatic co-morbid condition. The most com-
mon co-morbid conditions were musculoskeletal disor-
ders (32.2% in asthma and 27.3% in COPD),
hypertension (17.0% in asthma and 17.4% in COPD), and
cardiac disease (12.7% in asthma and19.3% in COPD).
The age- and gender-adjusted associations between
co-morbidity and HRQoL are presented in Table 2.
Although not all associations were statistically signi¢-
cant, overall, co-morbidity appeared to be negatively as-
sociated with HRQoL.When more than one co-morbid
condition was present, HRQoL was even poorer. This
was most apparent for general HRQoL in asthma pa-
tients; compared to no co-morbid conditions, one co-
morbid condition gave an odds ratio (OR) of 2.00, more
than one co-morbid condition an OR of 6.91. In asthma
patients, co-morbidity was associatedwith disease-spe-
ci¢c HRQoL, while in COPD patients no statistically sig-
ni¢cant association was observed. The ORs were
statistically signi¢cantly di¡erent between the two dis-
ease groups. Associations were stronger for general
than for disease-speci¢c HRQoL.
Multivariate associationsbetween speci¢c chronic dis-
eases and HRQoL can be found inTable 2 (total scores of
HRQoL) and Table 3 (subscales of HRQoL).The presence
of hypertension was statistically signi¢cantly associated
with poor disease speci¢c HRQoL in asthma patients
only. Especially the more ‘general’ subscales of the QoL-
RIQwere a¡ected (‘physical problems’,‘general activities’,
‘daily and domestic activities’, ‘social activities, relation-
ships and sexuality’).Cardiac diseasewas associatedboth
with poor disease-speci¢c and poor general HRQoL in
asthma patients. No associations were found in COPD
patients. Di¡erences between the two disease groups
were statistically signi¢cant. For cardiac disease, almost
all subscales of both questionnaires were a¡ected, in-
cluding ‘breathing problems’ of the QoL-RIQ. Musculos-
keletal disorders were associated with poor general
HRQoL in both asthma and COPD patients. Especially
the subscales ‘physical mobility’,‘sleep’,‘energy’, and ‘pain’
were a¡ected. Although the total score of the QoL-RIQ
was not statistically signi¢cantly associatedwith muscu-
loskeletal disorders, in COPD, some subscales of the
QoL-RIQ were in£uenced bymusculoskeletal disorders.
DISCUSSION
As far as we know, this is the ¢rst study examining in
detail the impact of co-morbidity on general and
disease-speci¢c HRQoL in both asthma and COPD
patients. The in£uence of somatic co-morbidity on
both disease-speci¢c and general HRQoL is examined
using three operational de¢nitions of co-morbidity:
TABLE 1. Characteristics of the studypopulations
Asthma
(n=395)
COPD
(n=161)
P-valuea
Age (mean7 SD) 54.0710.0 61.0710.3 o0.01
Gender (%male) 41.0 55.3 o0.01
FEV1%predicted (mean7 SD) 96.3716.1 60.7715.0 o0.01
Health-related quality of lifeb
QoL-RIQ [median (range)] 13.2 (7.1^36.7) 16.1 (7.1^35.9) o0.01
NHP [median (range)] 10.1 (0.0^81.5) 12.4 (0.0^73.0) o0.1
Number ofco-morbid conditions
No co-morbidity (%) 47.3 46.6 40.1
One co-morbid condition (%) 32.2 30.4
More than one co-morbid condition (%) 20.5 23.0
Speci¢c co-morbid conditions
Hypertension (%yes) 17.0 17.4 40.1
Cardiacdisease (%yes) 12.7 19.3 o0.1
Cardiac arrhythmia (%yes) 2.0 1.2 40.1
Myocardial infarction (%yes) 4.3 10.6 o0.01
Angina pectoris (%yes) 8.1 9.9 40.1
Congestive heart failure 1.8 3.7 40.1
Musculoskeletal disorders (%yes) 32.2 27.3 40.1
Arthritis (%yes) 25.1 23.0 40.1
Other (%yes) 8.4 6.2 40.1
Diabetesmellitus (%yes) 5.3 5.0 40.1
Cerebrovasculardisease (%yes) 3.5 2.5 40.1
Malignancies (%yes) 4.8 6.8 40.1
Other chronic diseases (%yes) 5.1 5.0 40.1
Remainingchronic diseasesc (%yes) 16.7 17.4 40.1
aDi¡erencesbetween asthma and COPDare testedusing the appropriate statistics.
bAhigher score indicates poorer HRQoL.
cIncludes: diabetesmellitus, cerebrovasculardisease, malignancies, and otherchronic diseases
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conditions; and (3) presence of speci¢c co-morbidity.
The reason for using three operational de¢nitions of co-
morbidity is that we want to get a complete picture of
the in£uence of co-morbidity on HRQoL. By using only
one de¢nition, relevant information might be missed.
Furthermore, the ¢rst two de¢nitionsmightbe interest-
ing for the purpose of epidemiological studies, while the
clinicianmightbemore interested in the third. It appears
that co-morbidity is an important determinant of dis-
ease-speci¢c HRQoL in asthma and of general HRQoL
in asthma and COPD. Especially, the presence of more
than one co-morbid condition increases the risk of poor
HRQoL.Cardiac disease andhypertension are associated
with poor disease-speci¢c HRQoL in asthma.Of all co-
morbid conditions, musculoskeletal disorders have the
greatest impact on a patient’s general HRQoL. Cardiac
disease is associated with HRQoL in asthma but not in
COPD.The ¢nding that co-morbidity is a determinant of
HRQoL in patients with asthma and COPD is supported
by others. In patients with COPD, co-morbidity was
found to be associated with general HRQoL (2,21) and,
less strongly, with disease-speci¢c HRQoL (2). Smeele
et al. (15) studied patients with chronic airway disease
and found that the presence of co-morbidity was asso-
ciatedwith both poor disease-speci¢c HRQoL and poor
general health status. The in£uence of co-morbidity on
HRQoL in asthma patients was not studied before.
The ¢nding that the in£uence of co-morbidity on
HRQoL is more pronounced in asthma than in COPD
patients, might be explained by di¡erences in disease
characteristics. Contrary to COPD, asthma patients
usually are not continuously confronted with complaints
due to pulmonary obstruction, but only during exacer-
bations. Therefore, the in£uence of a co-morbid
condition on HRQoL in asthma patients is likely to be
stronger than the in£uence in COPD patients who
TABLE 2. Results from logistic regression analyses with HRQoL as the dependent variable and co-morbid conditions as the
independent variables
QoL-RIQ total score
OR (95% CI)a
NHP total score OR (95% CI)a
Independent variables Asthma
(n=395)
COPD
(n= 161)
Asthma
(n = 395)
COPD
(n = 161)
Presence of co-morbidity
Yes 2.08 (1.37^3.18) 1.09 (0.55^2.17)b 2.96 (1.93^4.53) 1.81 (0.91^3.60)
Number ofco-morbid conditionsc
1condition 1.37 (0.86^2.20) 0.87 (0.41^1.87) 2.00 (1.26^3.20) 1.35 (0.63^2.87)
> 1condition 4.77 (2.62^8.69) 1.61 (0.64^4.07)b 6.91 (3.64^13.12) 3.22 (1.23^8.45)
Speci¢c co-morbid conditionsd
Hypertension 2.47 (1.37^4.43) 0.60 (0.25^1.44)b 1.79 (0.99^3.27) 2.05 (0.79^5.31)
Cardiacdisease 3.72 (1.82^7.62) 0.99 (0.41^2.39)b 2.28 (1.11^4.70) 0.61 (0.25^1.53)b
Musculoskeletal disorders 1.52 (0.96^2.40) 2.17 (0.95^4.98) 3.12 (1.95^4.99) 2.52 (1.10^5.78)
Remaining chronicdiseasese 1.62 (0.91^2.86) 1.58 (0.63^3.97) 2.14 (1.18^3.90) 2.22 (0.84^5.85)
aOddsratios (OR) + 95% con¢denceintervals (C.I.) arepresented.AnOR41indicates ahigherriskonpoorHRQoL.TheOR
is printedboldwhenthe association is statistically signi¢cant.All associations are adjusted for age andgender.
bThe ORis statistically signi¢cantlydi¡erent between asthma and COPD patients (Po 0.05).
cReference category = no co-morbid condition.
dAll co-morbid conditions are entered in amultivariatemodel.
eIncludes: diabetesmellitus, cerebrovasculardisease, malignancies, and otherchronic diseases.
472 RESPIRATORYMEDICINEalready experience chronic complaints and a poorer
HRQoL. Furthermore, comparable to other studies
examining the impact of co-morbidity on health
outcomes such as depression (22) or disability (23), there
appears to be a dose^response relation between
co-morbidity and HRQoL.
We found that the presence of hypertension is not as-
sociatedwith poor disease-speci¢cHRQoL in COPDpa-
tients and only weakly (not statistically signi¢cant) with
poor general HRQoL in both asthma and COPD pa-
tients, which is not really surprising since hypertension
does not cause direct physical complaints. Surprising,
however, is that in asthma patients, the presence of hy-
pertension is associated with poor disease-speci¢c
HRQoL. In a study done by Lawrence et al. (24), the pre-
sence of hypertension appeared to be associated with
reduced HRQoLwhen compared to a groupwithout hy-
pertension. It is possible that asthma patients are more
a¡ectedby thepresence of hypertension thanCOPDpa-
tients because of the di¡erences in disease characteris-
tics as mentioned before. A possible explanation for the
¢nding that disease-speci¢c HRQoL is more a¡ected
than general HRQoL may be that dyspnea is one of the
adverse e¡ects of commonly used antihypertensive
drugs. However, the association between hypertension
and disease-speci¢c HRQoL was notmodi¢ed by adjust-
ing for dyspnea (data not shown). Also bodymass index,
as a proxy measure for obstructive sleep apnea, did not
modify the association (data not shown).Another remarkable ¢nding, since cardiac disease is
one of the most frequent causes of death in COPD
(25,26), is the association between cardiac disease and
HRQoL in asthma, but not in COPD patients. Appar-
ently, although co-morbid cardiac disease is a risk factor
for mortality in COPD patients (27), it does not a¡ect
patients’ HRQoL. This theory is supported by Patrick
et al. (28), who found that adults with musculoskeletal
disorders report poorer general HRQoL than adults
with cardiac disease. So even though the prognosis for
survival may di¡er, patients with non-life-threatening
conditions may have poorer HRQoL than patients with
potentially life-threatening conditions. The ¢nding that
in asthma the presence of cardiac disease is associated
with HRQoL, while in COPD it is not, might also be
explained by di¡erences in disease characteristics. It is
possible that asthma patients are, more than COPD
patients, troubled by a potentially life-threatening and
socially limiting disease. However, subscale analyses in
asthma onlypartly support this hypothesis; the presence
of cardiac disease is associated with reduced disease-
speci¢c HRQoL for the subscale ‘social activities,
relationships and sexuality’, but no association is found
with general HRQoL according to the subscale ‘social
isolation’. Another explanation might be that patients
with angina pectoris (present in 64% of asthma patients
with cardiac disease) experience periodical chest pain
and dyspnea, especially with e¡ort, resembling dyspnea
due to asthma. In line with this theory, COPD patients
TABLE 3. Results fromlogistic regression analyseswith HRQoL (subscales) as the dependent variable and co-morbid conditions as the independent variables.
QoL-RIQ subscales
OR (95% C.I.)a
NHP subscales
OR (95% C.I.)a
Asthma
(n= 395)b
COPD
(n = 161)b
Asthma
(n= 395)
COPD
(n = 161)
Hypertension Hypertension
Physicalproblems 2.72 (1.52^4.88) 0.60 (0.25^1.46) Physicalmobility 2.74 (1.42^5.29) 2.23 (0.82^6.05)
General activities 1.92 (1.06^3.46) 0.63 (0.25^1.54) Sleep 1.01 (0.58^1.78) 0.87 (0.36^2.11)
Daily and domestic activities 1.92 (1.06^3.48) 1.44 (0.57^3.64) Energy 1.64 (0.92^2.94) 0.79 (0.33^1.90)
Emotions 1.78 (0.99^3.20) 2.02 (0.85^4.80) Emotionalreactions 1.15 (0.65^2.02) 1.69 (0.71^4.03)
Social activities, relationships and sexuality 2.25 (1.20^4.21) 0.62 (0.23^1.68) Social isolation 0.83 (0.40^1.73) 1.06 (0.40^2.83)
Breathingproblems (BPs) 1.46 (0.79^2.70) 0.89 (0.37^2.17) Pain 1.63 (0.86^3.01) 0.77 (0.29^2.06)
Situations triggering or enhancing BP 1.32 (0.75^2.33) 0.17 (0.06^0.46)
Cardiac disease Cardiac disease
Physicalproblems 2.85 (1.43^5.68) 1.17 (0.48^2.87) Physicalmobility 3.30 (1.45^7.51) 1.35 (0.51^3.52)
General activities 2.70 (1.38^5.31) 0.87 (0.36^2.12) Sleep 2.31 (1.16^4.56) 0.53 (0.22^1.30)
Daily and domestic activities 4.67 (2.21^9.89) 1.33 (0.54^3.27) Energy 2.00 (1.00^4.00) 0.68 (0.28^1.64)
Emotions 1.88 (0.96^3.66) 1.12 (0.44^2.82) Emotionalreactions 2.11 (1.09^4.09) 0.62 (0.26^1.47)
Social activities, relationships and sexuality 3.21 (1.51^6.84) 0.85 (0.32^2.25) Social isolation 1.37 (0.62^3.01) 0.67 (0.24^1.91)
(BPs) 2.49 (1.13^5.50) 0.80 (0.34^1.90) Pain 2.96 (1.44^6.09) 0.80 (0.31^2.09)
Situations triggering or enhancing BP 1.29 (0.67^2.49) 1.28 (0.50^3.26)
Musculoskeletal disorders Musculoskeletal disorders
Physicalproblems 1.42 (0.90^2.25) 2.39 (1.08^5.31) Physicalmobility 4.34 (2.63^7.18) 3.88 (1.58^9.50)
General activities 1.49 (0.91^2.45) 2.26 (1.05^4.89) Sleep 1.78 (1.14^2.79) 3.78 (1.64^8.74)
Daily and domestic activities 1.87 (1.17^2.97) 1.29 (0.58^2.89) Energy 2.51 (1.59^3.97) 2.80 (1.26^6.20)
Emotions 0.83 (0.50^1.40) 2.43 (1.11^5.30) Emotionalreactions 2.02 (1.29^3.15) 1.76 (0.82^3.78)
Social activities, relationships and sexuality 1.47 (0.87^2.46) 2.07 (0.85^5.06) Social isolation 1.65 (0.93^2.92) 2.26 (0.98^5.23)
(BPs) 1.53 (0.95^2.47) 0.99 (0.44^2.22) Pain 5.03 (3.07^8.24) 5.26 (2.34^11.83)
Situations triggering or enhancing BP 1.65 (1.05^2.58) 2.14 (0.88^5.20)
Sum score‘otherchronic diseases’ Sum score‘other chronic diseases’
Physicalproblems 1.90 (1.07^3.35) 1.63 (0.67^3.98) Physicalmobility 1.83 (0.97^3.45) 2.81 (1.00^7.88)
General activities 2.68 (1.51^4.78) 2.81 (1.16^6.78) Sleep 1.60 (0.91^2.81) 1.94 (0.77^4.87)
Daily and domestic activities 1.66 (0.92^2.30) 1.64 (0.65^4.17) Energy 2.11 (1.18^3.79) 1.75 (0.71^4.29)
Emotions 1.83 (1.02^3.30) 1.06 (0.43^2.64) Emotionalreactions 0.91 (0.52^1.60) 2.09 (0.86^5.10)
Social activities, relationships and sexuality 1.21 (0.63^2.29) 0.49 (0.19^1.29) Social isolation 2.58 (1.37^4.84) 1.67 (0.66^4.26)
(BPs) 1.36 (0.74^2.48) 1.26 (0.50^3.17) Pain 1.33 (0.71^2.49) 2.26 (0.89^5.72)
Situations triggering or enhancing BP 1.68 (0.94^2.95) 0.78 (0.30^2.04)
aOR+ 95%CIarepresented.AnOR41indicates ahigherriskonpoorHRQoL.TheORisprintedboldwhenthe associationis statistically signi¢cant.All associations are adjusted for
age, gender and all other reported chronic diseases.bFor the subscale‘Social activities, relationships and sexuality’, the numberof patients is 356 (asthma) and135 (COPD).
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dyspnea due to COPD, resulting in less complaints due
to angina pectoris and thus less additional e¡ect on
HRQoL. However, adjusting for dyspnea did not modify
the association between co-morbid cardiac disease and
HRQoL (data not shown).
The fact that musculoskeletal disorders appear to
have such a great impact on a patients’ general HRQoL
in both asthma and COPD, is in line with Patrick et al.
(28) as mentioned before. Additional support can be
found in Fried et al. (29), who found that, in older wo-
men, the presence of lung disease and arthritis were sy-
nergistically associated with disability. Xuan et al. (30)
found, among asthma patients, musculoskeletal disor-
ders (arthritis or back pain)was the only co-morbid con-
dition associated with both general and disease-speci¢c
HRQoL.
It can be argued that patients with co-morbidity may
have more severe asthma, thus explaining the impact of
co-morbidity on disease-speci¢c HRQoL. However, all
associations remained statistically signi¢cant after ad-
justing for pulmonary function and dyspnea (data not
shown), which does not support this theory.
Some methodological limitations of the study should
be mentioned. Regarding the external validity of the
study, one has to keep in mind that patients were re-
cruited from general practice, which is likely to result in
a patient group with a relatively mild disease severity.
Especially inCOPDpatients, co-morbidconditionsmight
therefore also be relatively mild or less frequent, com-
pared to, patients from outpatient clinics or hospitals.
As a result, associations between HRQoL and co-mor-
biditymight be underestimated, since themore extreme
end of the spectrum is missed.However, it is also possi-
ble that, in COPD patients, a more severe diseasewould
have masked the in£uence of co-morbidity. Regarding
the internal validity, self-report of co-morbid conditions
may have resulted in stronger associations between co-
morbidity and HRQoL, since over-reporting of co-mor-
bid conditions (especially more subjective complaints
such as back pain) may be related to reporting of poorer
HRQoL, while under-reportingmay be related to better
HRQoL. Although a substantial proportion of the initial
study population refused to participate or was excluded
due to missing data, we do not suspect a selection bias,
since no selective exclusion was observed with respect
to gender, age, and disease group (the latter could only
be examined for participating patients).
Concluding, in patients with asthma and COPD aged
40^75 years somatic co-morbidity is an important de-
terminant of HRQoL. Since co-morbidity is common in
patients over 40 years of age, excluding patients with
co-morbidity in clinical and descriptive studies does not
seem to be the right approach. Co-morbidity should be
taken into account as an important covariate in studies
with subjective health outcomes. Depending on the re-search question, severalways of expressing co-morbidity
might be considered.
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